FDA Approves Vaprisol
Vaprisol Astellas Pharma US, Inc. - Treatment for Euvolemic Hyponatremia
Vaprisol is an arginine vasopressin (AVP) antagonist indicated for the treatment of euvolemic hyponatremia in hospitalized patients.Posted: December 2005
Related articles
- FDA Approves Astellas' Vaprisol (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia - October 22, 2008
- FDA Approves Astellas' Vaprisol for the Treatment of Hypervolemic Hyponatremia - March 2, 2007
- FDA Issues Approvable Letter for Yamanouchi's Investigational Hyponatremia Treatment Conivaptan Hydrochloride Injection - December 1, 2004
- Yamanouchi Pharma America Submits New Drug Application to the FDA for Conivaptan Hydrochloride to treat Hyponatremia - February 2, 2004
Vaprisol (conivaptan hydrochloride) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
